Topical immunomodulators for atopic dermatitis

Current Opinion in Pediatrics

Volumn 14, Issue 4, 2002, Pages 414-418

  Bernard, Laurie A ^a   Eichenfield, Lawrence F ^a  

^a RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; IMMUNOMODULATING AGENT; PIMECROLIMUS; TACROLIMUS;

ASTHMA; ATOPIC DERMATITIS; CANCER RISK; CLINICAL TRIAL; CREAM; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FLU LIKE SYNDROME; HUMAN; IMMUNOPATHOLOGY; OINTMENT; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN CANCER; SKIN INFECTION; SKIN IRRITATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; CLINICAL TRIALS; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS;

EID: 0036067393     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200208000-00010     Document Type: Review

References (29)

1. The prevalence of atopic dermatitis in Oregon schoolchildren
2. Atopic dermatitis: A genetic-epidemiologic study in a population-based twin sample
3. Atopic dermatitis in pediatric patients: Perceptions of physicians and parents
4. Shifts in interleukin 4 and interferon γ production by T-cells of patients with elevated serum IgE levels and the modulatory effects of these lymphokines on spontaneous IgE synthesis
5. Granulocyte macrophage colony stimulating factor contributes to enhanced monocyte survival in chronic atopic dermatitis
6. The efficacy, tolerability and safety of a new oral formulation of Sandimmune-Neoral in severe refractory atopic dermatitis
7. Atopic-dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981
8. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin disease: In vitro pharmacology
9. A short-term trial of tacrolimus ointment for atopic dermatitis
10. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children
11. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients, part I: Efficacy
12. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients, part II: Safety
13. A 12 week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients
14. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis
15. FK 506 Ointment Study Group: Long-term treatment with FK 506 (tacrolimus) ointment in patients with atopic dermatitis: Analysis at the time of 2 year observation
16. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children
17. Long-term safety of topically applied tacrolimus ointment in pediatric patients 2-15 years of age with atopic dermatitis
18. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome
19. Safety and efficacy of ASM 981 cream 1% (pimecrolimus) in the treatment of atopic dermatitis in children and adolescents
20. Pimecrolimus (Elidel, SDZ ASM 981) cream 1% is effective and safe in infants aged 3-23 months with atopic dermatitis
21. Pimecrolimus cream reduces the number of flares and the need for topical corticosteroids in children with atopic dermatitis: A 12 month, double-blind, controlled study
22. Tacrolimus ointment improves psoriasis in a microplaque assay
23. Topical tacrolimus is effective for facial lesions of psoriasis
24. Inhibition of allergic contact reactions by topical FK 506
25. Topical tacrolimus for pyoderma gangrenosum
26. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease
27. Topical FK-506: A potent immunotherapy for alopecia areata? Studies using the experimental bald rat model
28. Rapid hair growth in refractory alopecia universalis associated with autoimmune disease following liver transplant and tacrolimus therapy